- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02443077
Ibrutinib antes y después del trasplante de células madre en el tratamiento de pacientes con linfoma difuso de células B grandes en recaída o refractario
Un estudio aleatorizado, doble ciego de fase III de ibrutinib durante y después del trasplante autólogo de células madre versus placebo en pacientes con linfoma difuso de células B grandes del subtipo de células B activadas en recaída o refractario
This randomized phase III trial studies ibrutinib to see how well it works compared to placebo when given before and after stem cell transplant in treating patients with diffuse large B-cell lymphoma that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). Before transplant, stem cells are taken from patients and stored. Patients then receive high doses of chemotherapy to kill cancer cells and make room for healthy cells. After treatment, the stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Ibrutinib is a drug that may stop the growth of cancer cells by blocking a protein that is needed for cell growth. It is not yet known whether adding ibrutinib to chemotherapy before and after stem cell transplant may help the transplant work better in patients with relapsed or refractory diffuse large B-cell lymphoma.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
- Otro: Laboratory Biomarker Analysis
- Droga: Cyclophosphamide
- Droga: Cytarabine
- Otro: Placebo Administration
- Droga: Ibrutinib
- Droga: Etoposide
- Droga: Melphalan
- Otro: Pharmacogenomic Study
- Procedimiento: Autologous Bone Marrow Transplantation
- Procedimiento: Autologous Hematopoietic Stem Cell Transplantation
- Droga: Carmustine
Descripción detallada
PRIMARY OBJECTIVE:
I. To evaluate the ability of ibrutinib to improve 24-month progression free survival (PFS) compared to placebo in patients with non-germinal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL) as determined by immunohistochemistry (IHC).
SECONDARY OBJECTIVES:
I. To evaluate the ability of ibrutinib to improve overall survival (OS) compared to placebo.
II. To evaluate the ability of ibrutinib to improve progression free survival (PFS) compared to placebo.
III. To evaluate the ability of ibrutinib to improve post-transplant response rates compared to placebo.
IV. To evaluate time to hematopoietic recovery in the two arms. V. To evaluate the safety and tolerability of ibrutinib compared to placebo. VI. To evaluate the incidence of secondary malignancies in the two arms. VII. To evaluate immune reconstitution in the two arms.
CORRELATIVE SCIENCE OBJECTIVES:
I. To assess whether pre-autologous hematopoietic stem cell transplantation (AutoHCT) positive fludeoxyglucose F-18 (FDG)-positron emission tomography (PET) is associated with inferior 24-month PFS as well as PFS and OS.
II. To assess whether pre-AutoHCT FDG-PET results are differentially associated with 24-month PFS, PFS and OS in the ibrutinib versus placebo arms.
III. To evaluate the application of the Lugano criteria and change in quantitative measurements between pre-AutoHCT and post AutoHCT (e.g. delta standard uptake variable [SUV], %SUV decline and %metabolic tumor volume [MTV] decline, and other available applicable quantitative measurements) to assess the association between changes in these variables and outcomes, such as PFS and OS.
IV. To assess whether the GSTT1 null polymorphism is correlated with pulmonary toxicity after BCNU (carmustine)-containing conditioning regimens as part of autologous stem cell transplantation.
V. To assess whether other polymorphisms in the BCNU metabolism pathway or BCNU damage repair pathway(s) are associated with pulmonary toxicity after BCNU-containing conditioning regimens as part of autologous stem cell transplantation.
VI. To evaluate whether any of the proposed deoxyribonucleic acid (DNA) polymorphisms are associated with other toxicities.
VII. To assess whether DLBCL subtype based on the lymphoma subtyping test (LST) is associated with 24-month PFS, PFS, and OS with ibrutinib compared to placebo in patients treated on this protocol.
VIII. To assess whether activating mutations in the BCR pathway are associated with response to ibrutinib and with clinical outcomes in patients treated on this protocol.
IX. To assess whether there are any phenotypic associations with IHC markers (particularly MYC protein expression level) and presence of these mutations.
X. To assess whether BCL2, MYC, and Ki67 expression by IHC affect clinical outcomes in patients treated on this protocol.
XI. To assess whether translocations in MYC with or without BCL2 and BC6 have poor outcomes in patients treated on this protocol and whether ibrutinib modifies the prognosis.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
CONDITIONING REGIMEN:
ARM I: Investigators may choose to use either the BEAMi (carmustine, etoposide, cytarabine, melphalan, ibrutinib) or CBVi (cyclophosphamide, carmustine, etoposide, ibrutinib) regimen.
BEAMi: Patients receive ibrutinib orally (PO) on days -6 to -1, carmustine intravenously (IV) over 2 hours on day -6, etoposide IV twice daily (BID) over 1-2 hours and cytarabine IV BID over 1-2 hours on days -5 to -2, and melphalan IV over 20-30 minutes on day -1. Optionally, if a day of rest is planned, patients may receive BEAMi on days -7 to -2.
CBVi: Patients receive ibrutinib PO on days -6 to -1, carmustine IV over 2 hours on day -6, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2. Optionally, if a day of rest is planned, patients may receive CBVi on days -7 to -2.
ARM II: Patients receive placebo PO on days -6 to -1 and receive 1 of the 2 conditioning regimens as in Arm I.
TRANSPLANT: In both arms, patients undergo autologous hematopoietic progenitor cell or bone marrow transplant on day 0.
CONTINUATION REGIMEN:
ARM I: Beginning 30-60 days after transplant, patients receive ibrutinib PO on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
ARM II: Beginning 30-60 days after transplant, patients receive placebo PO on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover Arm I.
After completion of treatment, patients are followed up every 6 months for up to 60 months from registration.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Riyadh, Arabia Saudita, 11211
- King Faisal Specialist Hospital and Research Centre
-
-
-
-
Alaska
-
Anchorage, Alaska, Estados Unidos, 98508
- Anchorage Associates in Radiation Medicine
-
Anchorage, Alaska, Estados Unidos, 99508
- Alaska Breast Care and Surgery LLC
-
Anchorage, Alaska, Estados Unidos, 99508
- Alaska Oncology and Hematology LLC
-
Anchorage, Alaska, Estados Unidos, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Estados Unidos, 99508
- Anchorage Oncology Centre
-
Anchorage, Alaska, Estados Unidos, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, Estados Unidos, 99508
- Providence Alaska Medical Center
-
Anchorage, Alaska, Estados Unidos, 99504
- Anchorage Radiation Therapy Center
-
Fairbanks, Alaska, Estados Unidos, 99701
- Fairbanks Memorial Hospital
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85719
- Banner University Medical Center - Tucson
-
Tucson, Arizona, Estados Unidos, 85719
- University of Arizona Cancer Center-North Campus
-
-
California
-
Burbank, California, Estados Unidos, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Duarte, California, Estados Unidos, 91010
- City of Hope Comprehensive Cancer Center
-
La Jolla, California, Estados Unidos, 92093
- UC San Diego Moores Cancer Center
-
Loma Linda, California, Estados Unidos, 92354
- Loma Linda University Medical Center
-
Los Angeles, California, Estados Unidos, 90048
- Cedars-Sinai Medical Center
-
Orange, California, Estados Unidos, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Sacramento, California, Estados Unidos, 95817
- University of California Davis Comprehensive Cancer Center
-
San Francisco, California, Estados Unidos, 94143
- UCSF Medical Center-Parnassus
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80012
- Rocky Mountain Cancer Centers-Aurora
-
Aurora, Colorado, Estados Unidos, 80012
- The Medical Center of Aurora
-
Aurora, Colorado, Estados Unidos, 80045
- UCHealth University of Colorado Hospital
-
Boulder, Colorado, Estados Unidos, 80303
- Boulder Community Foothills Hospital
-
Boulder, Colorado, Estados Unidos, 80304
- Rocky Mountain Cancer Centers-Boulder
-
Colorado Springs, Colorado, Estados Unidos, 80909
- UCHealth Memorial Hospital Central
-
Denver, Colorado, Estados Unidos, 80218
- Presbyterian - Saint Lukes Medical Center - Health One
-
Denver, Colorado, Estados Unidos, 80218
- Rocky Mountain Cancer Centers-Midtown
-
Denver, Colorado, Estados Unidos, 80220
- Rocky Mountain Cancer Centers-Rose
-
Denver, Colorado, Estados Unidos, 80204
- Denver Health Medical Center
-
Denver, Colorado, Estados Unidos, 80218
- Colorado Blood Cancer Institute
-
Denver, Colorado, Estados Unidos, 80209
- The Women's Imaging Center
-
Denver, Colorado, Estados Unidos, 80206
- National Jewish Health-Main Campus
-
Denver, Colorado, Estados Unidos, 80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Englewood, Colorado, Estados Unidos, 80113
- Mountain Blue Cancer Care Center - Swedish
-
Englewood, Colorado, Estados Unidos, 80113
- Swedish Medical Center
-
Fort Collins, Colorado, Estados Unidos, 80524
- Poudre Valley Hospital
-
Golden, Colorado, Estados Unidos, 80401
- National Jewish Health-Western Hematology Oncology
-
Grand Junction, Colorado, Estados Unidos, 81501
- Saint Mary's Hospital and Regional Medical Center
-
Grand Junction, Colorado, Estados Unidos, 81505
- Grand Valley Oncology
-
Greeley, Colorado, Estados Unidos, 80631
- Banner North Colorado Medical Center
-
Lafayette, Colorado, Estados Unidos, 80026
- Good Samaritan Hospital - Cancer Centers of Colorado
-
Littleton, Colorado, Estados Unidos, 80120
- Rocky Mountain Cancer Centers-Littleton
-
Lone Tree, Colorado, Estados Unidos, 80124
- Rocky Mountain Cancer Centers-Sky Ridge
-
Loveland, Colorado, Estados Unidos, 80539
- Banner North Colorado Medical Center - Loveland Campus
-
Wheat Ridge, Colorado, Estados Unidos, 80401
- Intermountain Health Lutheran Hospital
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06520
- Yale University
-
New Haven, Connecticut, Estados Unidos, 06510
- Smilow Cancer Center/Yale-New Haven Hospital
-
-
Delaware
-
Lewes, Delaware, Estados Unidos, 19958
- Beebe Medical Center
-
Newark, Delaware, Estados Unidos, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Estados Unidos, 19713
- Delaware Clinical and Laboratory Physicians PA
-
Newark, Delaware, Estados Unidos, 19713
- Medical Oncology Hematology Consultants PA
-
Newark, Delaware, Estados Unidos, 19718
- Christiana Care Health System-Christiana Hospital
-
Rehoboth Beach, Delaware, Estados Unidos, 19971
- Beebe Health Campus
-
Seaford, Delaware, Estados Unidos, 19973
- TidalHealth Nanticoke / Allen Cancer Center
-
Wilmington, Delaware, Estados Unidos, 19801
- Christiana Care Health System-Wilmington Hospital
-
-
Florida
-
Deerfield Beach, Florida, Estados Unidos, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Gainesville, Florida, Estados Unidos, 32610
- UF Health Cancer Institute - Gainesville
-
Miami, Florida, Estados Unidos, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Plantation, Florida, Estados Unidos, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
Tampa, Florida, Estados Unidos, 33612
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Emory University Hospital/Winship Cancer Institute
-
Atlanta, Georgia, Estados Unidos, 30342
- Northside Hospital
-
Augusta, Georgia, Estados Unidos, 30912
- Augusta University Medical Center
-
-
Idaho
-
Boise, Idaho, Estados Unidos, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Estados Unidos, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Estados Unidos, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Estados Unidos, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Estados Unidos, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Estados Unidos, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Estados Unidos, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Estados Unidos, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Estados Unidos, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Estados Unidos, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, Estados Unidos, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Northwestern University
-
Chicago, Illinois, Estados Unidos, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Estados Unidos, 60612
- University of Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- Rush MD Anderson Cancer Center
-
Maywood, Illinois, Estados Unidos, 60153
- Loyola University Medical Center
-
New Lenox, Illinois, Estados Unidos, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
-
Kansas
-
Chanute, Kansas, Estados Unidos, 66720
- Cancer Center of Kansas - Chanute
-
Dodge City, Kansas, Estados Unidos, 67801
- Cancer Center of Kansas - Dodge City
-
El Dorado, Kansas, Estados Unidos, 67042
- Cancer Center of Kansas - El Dorado
-
Fort Scott, Kansas, Estados Unidos, 66701
- Cancer Center of Kansas - Fort Scott
-
Independence, Kansas, Estados Unidos, 67301
- Cancer Center of Kansas-Independence
-
Kansas City, Kansas, Estados Unidos, 66160
- University of Kansas Cancer Center
-
Kingman, Kansas, Estados Unidos, 67068
- Cancer Center of Kansas-Kingman
-
Lawrence, Kansas, Estados Unidos, 66044
- Lawrence Memorial Hospital
-
Liberal, Kansas, Estados Unidos, 67905
- Cancer Center of Kansas-Liberal
-
Manhattan, Kansas, Estados Unidos, 66502
- Cancer Center of Kansas-Manhattan
-
McPherson, Kansas, Estados Unidos, 67460
- Cancer Center of Kansas - McPherson
-
Newton, Kansas, Estados Unidos, 67114
- Cancer Center of Kansas - Newton
-
Parsons, Kansas, Estados Unidos, 67357
- Cancer Center of Kansas - Parsons
-
Pratt, Kansas, Estados Unidos, 67124
- Cancer Center of Kansas - Pratt
-
Salina, Kansas, Estados Unidos, 67401
- Cancer Center of Kansas - Salina
-
Wellington, Kansas, Estados Unidos, 67152
- Cancer Center of Kansas - Wellington
-
Westwood, Kansas, Estados Unidos, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
Wichita, Kansas, Estados Unidos, 67214
- Ascension Via Christi Hospitals Wichita
-
Wichita, Kansas, Estados Unidos, 67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita, Kansas, Estados Unidos, 67214
- Cancer Center of Kansas - Wichita
-
Wichita, Kansas, Estados Unidos, 67208
- Associates In Womens Health
-
Winfield, Kansas, Estados Unidos, 67156
- Cancer Center of Kansas - Winfield
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40202
- The James Graham Brown Cancer Center at University of Louisville
-
-
Louisiana
-
Baton Rouge, Louisiana, Estados Unidos, 70806
- Baton Rouge General Medical Center
-
Baton Rouge, Louisiana, Estados Unidos, 70809
- Hematology/Oncology Clinic PLLC
-
New Orleans, Louisiana, Estados Unidos, 70112
- Tulane University School of Medicine
-
New Orleans, Louisiana, Estados Unidos, 70121
- Ochsner Medical Center Jefferson
-
Shreveport, Louisiana, Estados Unidos, 71103
- LSU Health Sciences Center at Shreveport
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Massachusetts
-
Fitchburg, Massachusetts, Estados Unidos, 01420
- Simonds-Sinon Regional Cancer Center
-
Worcester, Massachusetts, Estados Unidos, 01655
- UMass Memorial Medical Center - University Campus
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- University of Michigan Rogel Cancer Center
-
Battle Creek, Michigan, Estados Unidos, 49017
- Bronson Battle Creek
-
Detroit, Michigan, Estados Unidos, 48201
- Wayne State University/Karmanos Cancer Institute
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Estados Unidos, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Estados Unidos, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Estados Unidos, 49009
- Beacon Kalamazoo Cancer Center
-
Kalamazoo, Michigan, Estados Unidos, 49048
- Beacon Kalamazoo
-
Muskegon, Michigan, Estados Unidos, 49444
- Trinity Health Muskegon Hospital
-
Niles, Michigan, Estados Unidos, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores, Michigan, Estados Unidos, 49444
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Reed City, Michigan, Estados Unidos, 49677
- Corewell Health Reed City Hospital
-
Saint Joseph, Michigan, Estados Unidos, 49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, Estados Unidos, 49085
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Traverse City, Michigan, Estados Unidos, 49684
- Munson Medical Center
-
Wyoming, Michigan, Estados Unidos, 49519
- University of Michigan Health - West
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455
- University of Minnesota/Masonic Cancer Center
-
Rochester, Minnesota, Estados Unidos, 55905
- Mayo Clinic in Rochester
-
-
Missouri
-
Creve Coeur, Missouri, Estados Unidos, 63141
- Siteman Cancer Center at West County Hospital
-
St Louis, Missouri, Estados Unidos, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Estados Unidos, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Estados Unidos, 63104
- SSM Health Saint Louis University Hospital
-
-
Montana
-
Anaconda, Montana, Estados Unidos, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Estados Unidos, 59101
- Billings Clinic Cancer Center
-
Billings, Montana, Estados Unidos, 59101
- Saint Vincent Healthcare
-
Billings, Montana, Estados Unidos, 59102
- Saint Vincent Frontier Cancer Center
-
Bozeman, Montana, Estados Unidos, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Estados Unidos, 59405
- Great Falls Clinic
-
Great Falls, Montana, Estados Unidos, 59405
- Benefis Sletten Cancer Institute
-
Helena, Montana, Estados Unidos, 59601
- Saint Peter's Community Hospital
-
Kalispell, Montana, Estados Unidos, 59901
- Logan Health Medical Center
-
Missoula, Montana, Estados Unidos, 59802
- Saint Patrick Hospital - Community Hospital
-
Missoula, Montana, Estados Unidos, 59804
- Community Medical Center
-
-
Nebraska
-
Bellevue, Nebraska, Estados Unidos, 68123
- Nebraska Medicine-Bellevue
-
Omaha, Nebraska, Estados Unidos, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Estados Unidos, 68118
- Nebraska Medicine-Village Pointe
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New York
-
Buffalo, New York, Estados Unidos, 14263
- Roswell Park Cancer Institute
-
New York, New York, Estados Unidos, 10065
- NYP/Weill Cornell Medical Center
-
Oswego, New York, Estados Unidos, 13126
- Upstate Cancer Center at Oswego
-
Rochester, New York, Estados Unidos, 14642
- University of Rochester
-
Syracuse, New York, Estados Unidos, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Estados Unidos, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, Estados Unidos, 10467
- Children's Hospital at Montefiore
-
The Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center - Moses Campus
-
The Bronx, New York, Estados Unidos, 10461
- Montefiore Medical Center-Weiler Hospital
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Durham, North Carolina, Estados Unidos, 27710
- Duke University Medical Center
-
Winston-Salem, North Carolina, Estados Unidos, 27157
- Wake Forest University Health Sciences
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cleveland, Ohio, Estados Unidos, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Estados Unidos, 44195
- Cleveland Clinic Foundation
-
Columbus, Ohio, Estados Unidos, 43210
- Ohio State University Comprehensive Cancer Center
-
West Chester, Ohio, Estados Unidos, 45069
- University of Cincinnati Cancer Center-West Chester
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Bend, Oregon, Estados Unidos, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Estados Unidos, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Estados Unidos, 97015
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay, Oregon, Estados Unidos, 97420
- Bay Area Hospital
-
Newberg, Oregon, Estados Unidos, 97132
- Providence Newberg Medical Center
-
Ontario, Oregon, Estados Unidos, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Oregon City, Oregon, Estados Unidos, 97045
- Providence Willamette Falls Medical Center
-
Portland, Oregon, Estados Unidos, 97239
- Oregon Health and Science University
-
Portland, Oregon, Estados Unidos, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Portland, Oregon, Estados Unidos, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Estados Unidos, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Chadds Ford, Pennsylvania, Estados Unidos, 19317
- Christiana Care Health System-Concord Health Center
-
Danville, Pennsylvania, Estados Unidos, 17822
- Geisinger Medical Center
-
Hazleton, Pennsylvania, Estados Unidos, 18201
- Geisinger Medical Center-Cancer Center Hazleton
-
Lewisburg, Pennsylvania, Estados Unidos, 17837
- Geisinger Medical Oncology-Lewisburg
-
Lewistown, Pennsylvania, Estados Unidos, 17044
- Lewistown Hospital
-
Philadelphia, Pennsylvania, Estados Unidos, 19111
- Fox Chase Cancer Center
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- UPMC Hillman Cancer Center
-
Pottsville, Pennsylvania, Estados Unidos, 17901
- Geisinger Cancer Services-Pottsville
-
Scranton, Pennsylvania, Estados Unidos, 18510
- Community Medical Center
-
Selinsgrove, Pennsylvania, Estados Unidos, 17870
- Geisinger Medical Oncology-Selinsgrove
-
State College, Pennsylvania, Estados Unidos, 16801
- Geisinger Medical Group
-
Wilkes-Barre, Pennsylvania, Estados Unidos, 18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
South Carolina
-
Boiling Springs, South Carolina, Estados Unidos, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Charleston, South Carolina, Estados Unidos, 29425
- Medical University of South Carolina
-
Clinton, South Carolina, Estados Unidos, 29325
- Prisma Health Cancer Institute - Laurens
-
Easley, South Carolina, Estados Unidos, 29640
- Prisma Health Cancer Institute - Easley
-
Greenville, South Carolina, Estados Unidos, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Estados Unidos, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Estados Unidos, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Estados Unidos, 29605
- Prisma Health Cancer Institute - Butternut
-
Greenville, South Carolina, Estados Unidos, 29601
- Saint Francis Hospital
-
Greenville, South Carolina, Estados Unidos, 29605
- Prisma Health Greenville Memorial Hospital
-
Greer, South Carolina, Estados Unidos, 29650
- Prisma Health Cancer Institute - Greer
-
Seneca, South Carolina, Estados Unidos, 29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57105
- Avera Cancer Institute
-
-
Tennessee
-
Franklin, Tennessee, Estados Unidos, 37067
- Vanderbilt-Ingram Cancer Center Cool Springs
-
Memphis, Tennessee, Estados Unidos, 38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
Nashville, Tennessee, Estados Unidos, 37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville, Tennessee, Estados Unidos, 37204
- Vanderbilt Breast Center at One Hundred Oaks
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
-
Utah
-
American Fork, Utah, Estados Unidos, 84003
- American Fork Hospital / Huntsman Intermountain Cancer Center
-
Cedar City, Utah, Estados Unidos, 84720
- Sandra L Maxwell Cancer Center
-
Farmington, Utah, Estados Unidos, 84025
- Farmington Health Center
-
Logan, Utah, Estados Unidos, 84321
- Logan Regional Hospital
-
Murray, Utah, Estados Unidos, 84107
- Intermountain Medical Center
-
Ogden, Utah, Estados Unidos, 84403
- McKay-Dee Hospital Center
-
Provo, Utah, Estados Unidos, 84604
- Utah Valley Regional Medical Center
-
Riverton, Utah, Estados Unidos, 84065
- Riverton Hospital
-
Salt Lake City, Utah, Estados Unidos, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, Estados Unidos, 84106
- Utah Cancer Specialists-Salt Lake City
-
Salt Lake City, Utah, Estados Unidos, 84143
- LDS Hospital
-
South Jordan, Utah, Estados Unidos, 84009
- South Jordan Health Center
-
St. George, Utah, Estados Unidos, 84770
- Saint George Regional Medical Center
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22908
- University of Virginia Cancer Center
-
Richmond, Virginia, Estados Unidos, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Aberdeen, Washington, Estados Unidos, 98520
- Providence Regional Cancer System-Aberdeen
-
Anacortes, Washington, Estados Unidos, 98221
- Cancer Care Center at Island Hospital
-
Bellingham, Washington, Estados Unidos, 98225
- PeaceHealth Saint Joseph Medical Center
-
Centralia, Washington, Estados Unidos, 98531
- Providence Regional Cancer System-Centralia
-
Edmonds, Washington, Estados Unidos, 98026
- Swedish Cancer Institute-Edmonds
-
Everett, Washington, Estados Unidos, 98201
- Providence Regional Cancer Partnership
-
Issaquah, Washington, Estados Unidos, 98029
- Swedish Cancer Institute-Issaquah
-
Kennewick, Washington, Estados Unidos, 99336
- Kadlec Clinic Hematology and Oncology
-
Lacey, Washington, Estados Unidos, 98503
- Providence Regional Cancer System-Lacey
-
Longview, Washington, Estados Unidos, 98632
- PeaceHealth Saint John Medical Center
-
Seattle, Washington, Estados Unidos, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Estados Unidos, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Estados Unidos, 98195
- University of Washington Medical Center - Montlake
-
Seattle, Washington, Estados Unidos, 98112
- Kaiser Permanente Washington
-
Seattle, Washington, Estados Unidos, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, Estados Unidos, 98122-5711
- Swedish Medical Center-Cherry Hill
-
Seattle, Washington, Estados Unidos, 98109
- Fred Hutchinson Cancer Center
-
Shelton, Washington, Estados Unidos, 98584
- Providence Regional Cancer System-Shelton
-
Spokane, Washington, Estados Unidos, 99204
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
-
Spokane, Washington, Estados Unidos, 99218
- MultiCare Deaconess Cancer and Blood Specialty Center - North
-
Spokane Valley, Washington, Estados Unidos, 99216
- MultiCare Deaconess Cancer and Blood Specialty Center - Valley
-
Vancouver, Washington, Estados Unidos, 98664
- PeaceHealth Southwest Medical Center
-
Walla Walla, Washington, Estados Unidos, 99362
- Providence Saint Mary Regional Cancer Center
-
Yelm, Washington, Estados Unidos, 98597
- Providence Regional Cancer System-Yelm
-
-
Wisconsin
-
Burlington, Wisconsin, Estados Unidos, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Chippewa Falls, Wisconsin, Estados Unidos, 54729
- Marshfield Clinic-Chippewa Center
-
Eau Claire, Wisconsin, Estados Unidos, 54701
- Marshfield Medical Center-EC Cancer Center
-
Eau Claire, Wisconsin, Estados Unidos, 54701
- Marshfield Clinic Cancer Center at Sacred Heart
-
Fond du Lac, Wisconsin, Estados Unidos, 54937
- Aurora Health Center-Fond du Lac
-
Germantown, Wisconsin, Estados Unidos, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Estados Unidos, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Estados Unidos, 54311
- Aurora BayCare Medical Center
-
Kenosha, Wisconsin, Estados Unidos, 53142
- Aurora Cancer Care-Kenosha South
-
Ladysmith, Wisconsin, Estados Unidos, 54848
- Marshfield Medical Center - Ladysmith
-
Madison, Wisconsin, Estados Unidos, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marinette, Wisconsin, Estados Unidos, 54143
- Aurora Bay Area Medical Group-Marinette
-
Marshfield, Wisconsin, Estados Unidos, 54449
- Marshfield Medical Center-Marshfield
-
Marshfield, Wisconsin, Estados Unidos, 54449
- Marshfield Medical Center
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Medical College of Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Estados Unidos, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Estados Unidos, 53233
- Aurora Sinai Medical Center
-
Minocqua, Wisconsin, Estados Unidos, 54548
- Marshfield Medical Center - Minocqua
-
Oshkosh, Wisconsin, Estados Unidos, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine, Wisconsin, Estados Unidos, 53406
- Aurora Cancer Care-Racine
-
Rice Lake, Wisconsin, Estados Unidos, 54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan, Wisconsin, Estados Unidos, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Stevens Point, Wisconsin, Estados Unidos, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Summit, Wisconsin, Estados Unidos, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, Estados Unidos, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Wausau, Wisconsin, Estados Unidos, 54401
- Marshfield Clinic-Wausau Center
-
Wauwatosa, Wisconsin, Estados Unidos, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, Estados Unidos, 53227
- Aurora West Allis Medical Center
-
Weston, Wisconsin, Estados Unidos, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, Estados Unidos, 54494
- Marshfield Clinic - Wisconsin Rapids Center
-
-
Wyoming
-
Cheyenne, Wyoming, Estados Unidos, 82001
- Cheyenne Regional Medical Center-West
-
Cody, Wyoming, Estados Unidos, 82414
- Billings Clinic-Cody
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
PRE-REGISTRATION ELIGIBILITY CRITERIA (STEP 0)
-
Patients must have paraffin tissue from the diagnostic or relapse biopsy available to be submitted for central pathology review; this review is mandatory prior to registration to confirm eligibility and should be initiated as soon as possible
-
ELIGIBILITY CRITERIA (STEP 1)
-
Diagnosis of World Health Organization (WHO) diffuse large B-cell lymphoma, non-GCB by central review confirmation
-
Patient must be deemed eligible to proceed with high-dose chemotherapy and autologous stem cell transplantation by local transplant center
-
New York Heart Association class I or less; ordinary physical activity does not cause undue fatigue, palpitations, dyspnea, or angina pain; patients 60 years or older must have a left ventricular ejection fraction (LVEF) at rest >= 40% measured by echocardiogram or multi-gated acquisition (MUGA)
-
Diffusion capacity of the lung for carbon monoxide (DLCO) >= 40% of predicted (corrected or uncorrected for hemoglobin per institutional standards)
-
Forced expiratory volume in 1 second (FEV1) >= 40% of predicted (corrected or uncorrected for hemoglobin per institutional standards)
-
Forced vital capacity (FVC) >= 40% of predicted (corrected or uncorrected for hemoglobin per institutional standards)
-
Total bilirubin =< 1.5 x upper limit of normal (ULN) unless isolated hyperbilirubinemia attributed to Gilbert's syndrome
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
-
Creatinine =< 2.0 mg/dL OR creatinine clearance (calculated clearance permitted) >= 40 mL/min by Cockcroft-Gault formula
-
Prothrombin time (PT)/ international normalized ration (INR) < 1.5 x ULN and partial thromboplastin time (PTT) (activated [a]PTT) < 1.5 x ULN
-
Patient must have progressed or be refractory to prior anthracycline-containing chemotherapy (e.g. rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone [R-CHOP], dose adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab [DA-EPOCH-R], etc)
-
No more than 3 prior regimens for large cell component (e.g. one induction and two salvage therapies); monoclonal antibody alone or involved field/involved site radiotherapy do not count as lines of therapy. Prior CART therapy is allowed and counts as one line of therapy
-
Prior use of ibrutinib is allowed unless patient has had disease progression while receiving ibrutinib
-
Patient must have chemosensitive disease as defined by at least a partial response to salvage therapy at their latest assessment
-
No major surgery =< 7 days prior to registration and no minor surgery =< 3 days prior to registration (with the exception of intravenous access placement, e.g. Hickman or peripherally inserted central catheter [PICC])
-
Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects; therefore, for women of childbearing potential only, a negative serum pregnancy test must be obtained within 14 days prior to registration
- Women of childbearing potential must use adequate contraception from study start to one month after the last dose of protocol therapy; adequate contraception is defined as hormonal birth control, intrauterine device, double barrier method or total abstinence; men must practice complete abstinence or agree to use an adequate contraception method from study start to one month after the last dose of protocol therapy
-
Age >= 18 years
-
Patients should not require chronic use of strong CYP3A inhibitors or strong CYP3A inducers
-
Patients should not require concurrent therapeutic doses of steroids (> 20 mg of prednisone/day or equivalent) unless they need them for the indications; steroids should be discontinued for 14 days before starting protocol treatment
-
Human immunodeficiency virus (HIV) infected patients are eligible provided they meet all other eligibility criteria, and:
- There is no prior history of acquired immunodeficiency syndrome (AIDS) defining conditions other than historically low CD4+ T-cell count or B-cell lymphoma
- In the opinion of an expert in HIV disease, prospects for long-term survival are excellent were it not for the diagnosis of lymphoma
- Use of HIV protease inhibitors as part of the anti-HIV regimen OR as a pharmacologic booster is not allowed
- Zidovudine is not allowed
- Once daily combination pills for HIV containing a pharmacologic booster such as cobicistat are not allowed
- Patients with multi-drug resistant HIV are not eligible
-
Patients cannot have:
- Active central nervous system or meningeal involvement by lymphoma; patients with a history of central nervous system (CNS) or meningeal involvement must be in a documented remission by cerebrospinal fluid (CSF) evaluation and contrast-enhanced magnetic resonance imaging (MRI) imaging for at least 91 days prior to registration
- Evidence of myelodysplasia or cytogenetic abnormality indicative of myelodysplasia on any bone marrow biopsy prior to initiation of therapy
- A known bleeding diathesis
- Requirement for warfarin or similar vitamin K antagonists; these drugs are prohibited 28 days prior to the first treatment and throughout the trial
- History of stroke or intracranial hemorrhage =< 6 months before treatment
- Currently active, clinically significant hepatic impairment (Child-Pugh class B or C according to the Child Pugh classification
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or other agents used in study
- Serologic status reflecting active hepatitis B or C infection; patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment; (PCR positive patients will be excluded)
-
Eastern Cooperative Oncology Group (ECOG) performance status must be =< 2
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Arm I (ibrutinib, chemotherapy, autoHCT)
CONDITIONING REGIMEN: Investigators may choose to use either the BEAMi or CBVi regimen. BEAMi: Patients receive ibrutinib PO on days -6 to -1 or days -7 to -2 if a day of rest is planned, carmustine IV over 2 hours on day -6, etoposide IV BID over 1-2 hours and cytarabine IV BID over 1-2 hours on days -5 to -2, and melphalan IV over 20-30 minutes on day -1. CBVi: Patients receive ibrutinib PO on days -6 to -1 or days -7 to -2 if a day of rest is planned, carmustine IV over 2 hours on day -6, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2. TRANSPLANT: In both arms, patients undergo autologous hematopoietic progenitor cell or bone marrow transplant on day 0. CONTINUATION REGIMEN: Beginning 30-60 days after transplant, patients receive ibrutinib PO on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. |
Correlative studies Given IV
Otros nombres:
Given IV
Otros nombres:
Given PO
Otros nombres:
Given IV
Otros nombres:
Given IV
Otros nombres:
Correlative studies
Otros nombres:
Undergo autologous hematopoietic progenitor cells or bone marrow transplant
Otros nombres:
Undergo autologous hematopoietic progenitor cells or bone marrow transplant
Otros nombres:
Given IV
Otros nombres:
|
|
Comparador de placebos: Arm II (placebo, chemotherapy, autoHCT)
CONDITIONING REGIMEN: Patients receive placebo PO on days -6 to -1 and receive 1 of the 2 conditioning regimens as in Arm I. TRANSPLANT: Patients undergo autologous hematopoietic progenitor cell or bone marrow transplant on day 0. CONTINUATION REGIMEN: Beginning 30-60 days after transplant, patients receive placebo PO on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover Arm I. |
Correlative studies Given IV
Otros nombres:
Given IV
Otros nombres:
Given PO Given IV
Otros nombres:
Given IV
Otros nombres:
Correlative studies
Otros nombres:
Undergo autologous hematopoietic progenitor cells or bone marrow transplant
Otros nombres:
Undergo autologous hematopoietic progenitor cells or bone marrow transplant
Otros nombres:
Given IV
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
24-month Progression-free Survival (PFS), Defined as the Proportion of Patients Who Are Alive and Progression-free 2 Years From Randomization
Periodo de tiempo: Time between registration and disease progression or death, whichever comes first, assessed at 24 months
|
Will be assessed using the Lugano classification. |
Time between registration and disease progression or death, whichever comes first, assessed at 24 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overall Survival (OS)
Periodo de tiempo: The time between randomization and death from any cause, assessed up to 5 years (60 months)
|
For each arm, the distribution of OS will be estimated using the Kaplan-Meier method. OS will be compared between the two arms using the log-rank test and Cox regression method adjusting for the known predictors. |
The time between randomization and death from any cause, assessed up to 5 years (60 months)
|
|
Time to Hematopoietic Engraftment
Periodo de tiempo: First day of one week without platelet transfusion, assessed up to 5 years
|
Will be defined as platelet count greater than or equal to 20,000/uL following nadir. |
First day of one week without platelet transfusion, assessed up to 5 years
|
|
PFS
Periodo de tiempo: Time between registration and disease progression or death, whichever comes first, assessed up to 5 years (60 months)
|
For each arm, the distribution of PFS will be estimated using the Kaplan-Meier method. PFS will be compared between the two arms using the log-rank test and Cox regression method adjusting for the known predictors. |
Time between registration and disease progression or death, whichever comes first, assessed up to 5 years (60 months)
|
|
Response Rate Using the Lugano Classification
Periodo de tiempo: Up to 60 months
|
The metabolic response proportion following AutoHCT will be compared between the two arms using chi-squared test. |
Up to 60 months
|
|
Treatment-related Mortality
Periodo de tiempo: Up to 60 months
|
Treatment-related mortality will be summarized using contingency tables. |
Up to 60 months
|
|
Incidence of Hematologic Toxicity of Ibrutinib Therapy
Periodo de tiempo: Up to 60 months
|
Hematologic toxicity will be summarized using contingency tables. |
Up to 60 months
|
|
Incidence of Secondary Malignancies
Periodo de tiempo: Up to 60 months
|
Incidence of secondary malignancies will be summarized using contingency tables. |
Up to 60 months
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Fludeoxyglucose Positron Emission Tomography (FDG-PET) Imaging Results
Periodo de tiempo: Baseline
|
PFS and OS will be compared between PET/computed tomography (CT) positive and negative groups using the two-sample log-rank test with a 2-sided alpha of 5%. A Cox regression model will be conducted to regress PFS and OS on PET/CT positivity. Deauville criteria analyses will be conducted with cutoffs at scores of 2 and 3, and quantitative measurements, e.g. delta standard uptake value (SUV), %SUV decline and %MTV decline, in place of the dichotomous FDG-PET/CT outcome. Positive/negative predictive values, sensitivity and specificity of PET/CT further estimated by dichotomizing the PFS and OS at 2 years. |
Baseline
|
|
GSTT1 Null Allele Expression
Periodo de tiempo: Baseline
|
GSTT1 null allele expression will be associated with carmustine toxicity. Quantified using the standard Common Terminology Criteria for Adverse Events and changes in diffusing capacity of the lungs for carbon monoxide from baseline. |
Baseline
|
|
Single-nuclear Polymorphisms (SNPs) in the BCNU Metabolism or Damage Repair Pathways
Periodo de tiempo: Baseline
|
All SNPs will be evaluated for deviation from Hardy-Weinberg. In the absence of a hypothesized effect, analyses will be powered for allele dosing (i.e., additive) effects. The Cochran-Armitage test (for binary endpoints), Jonkheere-Terpstra test (for quantitative traits including biomarker or gene expressions in serum or tumor ribonucleic acid) and the Cox score test (for censored time-to-event outcomes) will be used to quantify marginal associations. Multivariable models, with molecular, clinical and demographic variables, will be constructed using conditional inference trees and random forests. |
Baseline
|
|
BCR Pathway Mutations
Periodo de tiempo: Baseline
|
The mutation of CD79a/b, caspase recruitment domain family, member 11 (CARD11), tumor necrosis factor, alpha-induced protein 3 TNFAIP3), and myeloid differentiation primary response 88 (MYD88) will be associated with each outcome in the ibrutinib arm (Arm A) using the chi-squared test for response rate and the log-rank test for each censored outcome. Similar analyses will be conducted for the placebo arm (Arm B) to show that the association between mutation and the outcomes observed in the ibrutinib arm is not observed in the placebo arm. |
Baseline
|
|
BCL2, MYC, and Ki67 Expression in Tissue Samples by Immunohistochemistry (IHC)
Periodo de tiempo: Baseline
|
The expression of BCL2, MYC, and Ki67 will be analyzed to assess whether they affect clinical outcomes. |
Baseline
|
|
MYC Translocations
Periodo de tiempo: Baseline
|
Translocations in MYC with or without BCL2, and BCL6 will be analyzed to determine whether they are related to poor outcomes and whether ibrutinib modifies the prognosis. |
Baseline
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Charalambos B Andreadis, Alliance for Clinical Trials in Oncology
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimado)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Aminoácidos, péptidos y proteínas
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Técnicas de investigación
- Terapéutica
- Técnicas de laboratorio clínico
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Procedimientos quirúrgicos, operativo
- Ácidos nucleicos, nucleótidos y nucleósidos
- Hidrocarburos
- Hidrocarburos, cíclico
- Carbohidratos
- Podoflotoxina
- Tetrahidronaftalenos
- Naftalenos
- Hidrocarburos aromáticos policíclicos
- Hidrocarburos, aromáticos
- Compuestos policíclicos
- Glucósidos
- Glucósidos
- Trasplante
- Amidas
- Aminoácidos
- Citidina
- Nucleósidos de pirimidina
- Pirimidinas
- Servicios de salud
- Instalaciones de atención médica Fuerza laboral y servicios
- Servicios de salud preventivos
- Mostaza de fosforamida
- Compuestos de mostaza de nitrógeno
- Compuestos de mostaza
- Hidrocarburos, halogenados
- Fosforamidas
- Compuestos organofosforados
- Nucleósidos
- Arabinonucleósidos
- Trasplante de células
- Terapia basada en células y tejidos
- Terapia biológica
- Fenilalanina
- Aminoácidos, aromáticos
- Aminoácidos, cíclico
- Prueba genética
- Técnicas genéticas
- Servicios genéticos
- Servicios de diagnóstico
- Compuestos de nitrosourea
- Urea
- Compuestos nitrosos
- Trasplante de tejido
- Ciclofosfamida
- Citarabina
- Carmustina
- Melfalán
- Etopósido
- Trasplante de células madre
- ibrutinib
- Prueba farmacogenómica
- Trasplante de médula ósea
Otros números de identificación del estudio
- NCI-2015-00668
- U10CA180821 (Subvención/contrato del NIH de EE. UU.)
- NCI-2015-00668 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- BMT CTN 1201
- A051301 (Otro identificador: CTEP)
- A051301
- A051301 (Otro identificador: Alliance for Clinical Trials in Oncology)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .